Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mestinon and Salbutamol for Post-COVID-19 Myopathy
2021-002610-14Phase 4Completed
- Sponsor
- Aarhus University Hospital
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of pyridostigmine and salbutamol in myopathies and muscle weakness (2 arms), sponsored by Aarhus University Hospital. Primary endpoint: Fatigue (Neuro-QoL Fatigue Scale). Started Jun 2021; status: completed.
02
Drugs
pyridostigminesalbutamol
03
Conditions
myopathiesmuscle weakness
Beyond the preview
Go deeper on 2021-002610-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002610-14.